Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liquid Metformin PK and Bioavailability Study
NCT07300007Phase 1Not yet recruiting
- Sponsor
- Aspargo Laboratories
- Start
- Mar 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM), sponsored by Aspargo Laboratories. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07300007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300007.